Infection with hepatitis C virus as a cause of nervous system disorders

Krystian Ślusarz, Patrycja Łanowy, Weronika Pyka, Bartosz Bijak, Miłosz Bichalski, Jakub Dzindzio, Jerzy Jaroszewicz


Hepatitis C is a disease caused by hepatitis C virus (HCV), which prevalence may reach over 5% in some countries. Untreated infection may lead to death due to cirrhosis or hepatocellular carcinoma. Almost 80% of infected patients occurs as asymptomatic. Symptoms of hepatitis C may include jaundice, nausea, vomiting, fever or muscle and joint pains. Even half of the patients experience nervous system disorders, due to the affinity of some types of HCV to nerve cells. It is also estimated that up to 30% of patients with chronic hepatitis C will develop cirrhosis within 25-30 years. Currently, the vast majority of infected patients can be cured thanks to the introduction of direct-acting antivirals (DAAs).


hepatitis C virus; HCV; neurocognitive disorders; nervous system disorders

Full Text:



Coppola N, Alessio L, Onorato L et al. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infect Dis Poverty. 2019;8(1):17.

Cloherty G, Talal A, Coller K et al. Role of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus Infection. J Clin Microbiol. 2016;54(2):265–273.

Irshad M, Mankotia DS, Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol. 2013;19(44):7896–7909.

Uliana CV, Riccardi CS, Yamanaka H. Diagnostic tests for hepatitis C: recent trends in electrochemical immunosensor and genosensor analysis. World J Gastroenterol. 2014;20(42):15476–15491.

Russelli G, Pizzillo P, Iannolo G et al. HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation. PLoS One. 2017;12(7):e0181683.

Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol. 2015;7(10):1377–1389.

Adland E, Jesuthasan G, Downs L et al. Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort. BMC Infect Dis. 2018;18(1):461.

Fourati S, Feld JJ, Chevaliez S, Luhmann N. Approaches for simplified HCV diagnostic algorithms. J Int AIDS Soc. 2018;21(Suppl Suppl 2):e25058.

Kumar A, Rajput MK, Paliwal D et al. Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries. Indian J Med Res. 2018;147(5):445–455.

Cipriano LE, Goldhaber-Fiebert JD. Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy Pract. 2018;3(1):2381468318776634.

Wasitthankasem R, Vichaiwattana P, Auphimai C et al. HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs. PeerJ. 2017;5:e4008.

Wang LS, D’Souza LS, Jacobson IM. Hepatitis C-A clinical review. Journal of Medical Virology. 2016;88(11):1844-55.

Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterology Clinics of North America. 2015;44(4):717–734.

Chan DP, Sun HY, Wong HT et al. Sexually acquired hepatitis C virus infection: a review. International Journal of Infectious Diseases. 2016;49:47-58.

Nazir N, Jan MR, Ali A et al. Prevalence of hepatitis-C virus genotypes and potential transmission risks in Malakand Khyber Pakhtunkhwa, Pakistan. Virol J. 2017;14:160.

Indolfi G, Nesi A, Resti M. Intrafamilial transmission of hepatitis C virus. Journal of Medical Virology. 2015:85:608–614.

Walczak-Koszela I, Sysa-Jędrzejowska A, Woźniacka A. Dermatozy współistniejące z wirusowymi chorobami wątroby. Postepy Hig Med Dosw. 2015:69:1325-1330.

Tampaki M, Koskinas J. Extrahepatic immune related manifestations in chronic hepatitis C virus infection. World J Gastroenterol. 2014;20(35): 12372-12380.

Polo ML, Laufer N. Extrahepatic manifestations of HCV: the role of direct acting antivirals. Expert Rev Anti Infect Ther. 2017;15(8):737-746.

Goossens N, Negro F. Cardiovascular Manifestations of Hepatitis C Virus. Clinics in Liver Disease, 21(3), 465–473.

Rosenthal, E., & Cacoub, P. Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus, 24(4-5), 469–482.

Domont, F., & Cacoub, P. (2016). Chronic hepatitis C virus infection, a new cardiovascular risk factor?. Liver International, 36(5), 621-627.

Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, Zampino R, Rinaldi L, Sellitto A, Giordano M, Marrone A. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol. 2015;21(8):2269-80.

Senzolo M, Schiff S, D'Aloiso CM, Crivellin C, Cholongitas E, Burra P, Montagnese S. Neuropsychological alterations in hepatitis C infection: the role of inflammation. World J Gastroenterol. 2011;17(29):3369-74.

Fletcher NF, McKeating JA. J Viral Hepat. Hepatitis C virus and the brain. 2012;19(5):301-6.

Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol. 2004;78(10):5170-83.

Shilu M, Muhammed F, Sara MI, Waqas I, Bisma R,Kaneez F, Ishtiaq Q. Hepatitis C virus and neurological damage. World J Hepatol. 2016;8(12): 545–556.

Monaco S, Ferrari S, Gajofatto A, Zanusso G, Mariotto S. HCV-related nervous system disorders. Clin Dev Immunol. 2012; 2012:236148.

Origgi L, Vanoli M, Carbone A, Grasso M, Scorza R. Central nervous system involvement in patients with HCV-related cryoglobulinemia. Am J Med Sci. 1998;315(3):208-10.

Adinolfi LE, Restivo L, Guerrera B, Sellitto A, Ciervo A, Iuliano N, Rinaldi L, Santoro A, Li Vigni G, Marrone A. Chronic HCV infection is a risk factor of ischemic stroke. Atherosclerosis. 2013;231(1):22-6.

Origgi L, Vanoli M, Carbone A, Grasso M, Scorza R. Central nervous system involvement in patients with HCV-related cryoglobulinemia. Am J Med Sci. 1998;315(3):208-10.

Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, Zampino R, Rinaldi L, Sellitto A, Giordano M, Marron A. Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview. World J Gastroenterol. 2015;21(8):2269–2280

Enger C, Forssen UM, Bennett D, Theodore D, Shantakumar S, McAfee A. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv Ther. 2014;31(8):891-903.

Gutierrez J, Elkind MSV. Chronic inflammatory diseases and stroke: Evidence for heterogeneous mechanisms. Ann Neurol. 2012;72:S6–S7.

Hsu CS, Kao JH, Chao YC, Lin HH, Fan YC, Huang CJ, Tsai PS. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther. 2013;38(4):415-23.

Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013;37(6):647-52.

Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, Stamataki Z, Meredith LW, Rowe IA, Luo G, Lopez-Ramirez MA, Baumert TF, Weksler B, Couraud PO, Kim KS, Romero IA, Jopling C, Morgello S, Balfe P, McKeating JA. Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology. 2012;142(3):634-643.

Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, Florio A, Loria P. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20(13):3410-7.

Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke. 2006;37(7):1923-32.

Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, Romano C, Adinolfi LE. Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol. 2013;5(10): 528–540

Bolay H, Söylemezoğlu F, Nurlu G, Tuncer S, Varli K. PCR detected hepatitis C virus genome in the brain of a case with progressive encephalomyelitis with rigidity. Clin Neurol Neurosurg. 1996;98(4):305-8.

Grewal AK, Lopes MB, Berg CL, Bennett AK, Alves VA, Trugman JM. Recurrent demyelinating myelitis associated with hepatitis C viral infection. J Neurol Sci. 2004;224(1-2):101-6.

Sacconi S, Salviati L, Merelli E. Acute disseminated encephalomyelitis associated with hepatitis C virus infection. Arch Neurol. 2001;58(10):1679-81.

Bieliauskas LA, Back-Madruga C, Lindsay KL, Wright EC, Kronfol Z, Lok AS, Fontana RJ, Halt-C Trial Group. Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C. J Int Neuropsychol Soc. 2007;13(4):687-92.

Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, Wesnes KA, Taylor-Robinson SD. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35(2):433-9.

Cherner M, Letendre S, Heaton RK, Durelle J, Marquie-Beck J, Gragg B, Grant I, HIV Neurobehavioral Research Center Group. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine Neurology. 2005;64(8):1343-7.

Martin EM, Novak RM, Fendrich M, Vassileva J, Gonzalez R, Grbesic S, Nunnally G, Sworowski L. Stroop performance in drug users classified by HIV and hepatitis C virus serostatus. J Int Neuropsychol Soc. 2004;10(2):298-300.

Chiu WC, Tsan YT, Tsai SL, Chang CJ, Wang JD, Chen PC, Health Data Analysis in Taiwan (hDATa) Research Group. Hepatitis C viral infection and the risk of dementia. Eur J Neurol. 2014;21(8):1068-e59.

Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002;35(2):440-6.

Córdoba J, Flavià M, Jacas C, Sauleda S, Esteban JI, Vargas V, Esteban R, Guardia J. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol. 2003;39(2):231-8.

Tillmann HL. Hepatitis C virus infection and the brain. Metab Brain Dis. 2004;19(3-4:351-6.

Goh J, Coughlan B, Quinn J, O'Keane JC, Crowe J. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 1999;11(8):833-8.

Carta MG, Angst J, Moro MF, Mura G, Hardoy MC, Balestrieri C, Chessa L, Serra G, Lai ME, Farci P. Association of chronic hepatitis C with recurrent brief depression. J Affect Disord. 2012;141(2-3):361-6.

Navinés R, Castellví P, Moreno-España J, Gimenez D, Udina M, Cañizares S, Diez-Quevedo C, Valdés M, Solà R, Martín-Santos R. Depressive and anxiety disorders in chronic hepatitis C patients: reliability and validity of the Patient Health Questionnaire. J Affect Disord. 2012;138(3):343-51.

Rifai MA, Gleason OC, Sabouni D. Psychiatric Care of the Patient With Hepatitis C: A Review of the Literature Prim Care Companion J Clin Psychiatry. 2010;12(6).

Mathew S, Faheem M, Ibrahim SM, et al. Hepatitis C virus and neurological damage. World J Hepatol. 2016;8(12):545–556.

McMahon JM, Tortu S. A potential hidden source of hepatitis C infection among noninjecting drug users. J Psychoactive Drugs. 2003;35:455–460.

European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017 Jan;66(1):153-194.

Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks post-treatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010;51:1122–1126.

Ansaldi F, Orsi A, Sticchi L, et al. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol. 2014 Aug 7;20(29):9633-52.

European Association for Study of the Liver Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237–264.

Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015 Mar 21;385(9973):1124-35.

Chevaliez S, Bouvier-Alias M, Brillet R et al. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009;4 e8209.

D'Ambrosio R, Degasperi E, Colombo M, Direct-acting antivirals: the endgame for hepatitis C? Curr Opin Virol. 2017 Jun;24:31-37.

Kohli A, Shaffer A, Sherman A, et al. Treatment of hepatitis C: a systematic review. JAMA. 2014 Aug 13;312(6):631-40.

Hézode C, Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions. J Viral Hepat. 2017 Feb;24(2):92-101.

Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015 Dec; 44(4):717-34.

Di Bisceglie AM.Natural history of hepatitis C: its impact on clinical management. Hepatology 2000; 31: 1014-1018.

Naveau S, Perlemuter G, Balian A. Epidemiology and natural history of cirrhosis. Rev Prat 2005; 55.

Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.

Anthony PP, Ishak KG, Nayak NC et al. Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol 1978; 31: 395-414.

Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23(6):1334–40.

Chang PE, Wong GW, Li JW et al. Epidemiology and Clinical Evolution of Liver Cirrhosis in Singapore. Ann Acad Med Singapore. 2015 Jun;44(6):218-25.

Barnett R. Liver cirrhosis. Lancet. 2018 Jul 28;392(10144):275.

Anand BS. Cirrhosis of liver. West J Med. 1999 Aug;171(2):110-5.

Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol. 2015 Jun;21(2):105-140.

Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017 Mar;34(2):153-159.

Polo ML, Laufer N. Extrahepatic manifestations of HCV: the role of direct acting antivirals. Expert Rev Anti Infect Ther. 2017 Aug;15(8):737-746.

Zignego AL, Ramos-Casals M, Ferri C et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017 May;16(5):523-541.

Ansaldi F, Orsi A, Sticchi L et al. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol. 2014 Aug 7;20(29):9633-52.

World Health Organization. Prevention and control of viral hepatitis infection: framework for global action. Available at:



  • There are currently no refbacks.

Copyright (c) 2019 © The Authors

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:

Journal Language(s): English 

PBN Poland



Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2 Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase


Universal Impact Factor 1.78 for year 2012. (

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski